MedTrace Logo

Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding

NCT04358016 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2020-04-22

No results posted yet for this study

Summary

The investigators studied the renal function index level in terlipressin treated cirrhotic patients with upper-gastrointestinal bleeding at different time point.

Conditions

  • Cirrhosis, Liver
  • Upper Gastrointestinal Bleeding

Interventions

DRUG

Terlipressin

Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding

DRUG

Somatostatin

Somatostatin

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Xuesong Liang, Dr · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-01-01
Completion
2020-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04358016 on ClinicalTrials.gov